Preclinical studies demonstrated its efficacy in inhibiting angiogenesis and tumor cell proliferation, particularly in FGFR1-amplified lung cancers and FGFR2-mutant endometrial cancers207,.216. Here, FGFR2 is linked to neoplasm.